The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study.

ABSTRACT:

Background

Thymosin α1 therapy was commonly used in patients with coronavirus disease 2019 (COVID-19), while its impact on outcomes and which patients could benefit from thymosin α1 therapy were uncertain.

Study design and methods

Patients with COVID-19 from 19 designated hospitals between January 1 to February 29, 2020 were included, and the main exposure of interest was administration of thymosin α1. The primary outcome was 28-day mortality. Propensity score matching (PSM) was used to account for baseline confounders, cluster analysis and Cox proportional hazard model was used to account for subgroup analysis.

Results

A total of 771 patients were included, and 327/771 (42.4%) patients received thymosin α1 therapy. The 28-day mortality in thymosin group was significa

SUBMITTER: Sun Q 

PROVIDER: S-EPMC7604217 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature